BIO Commends Senate for Approval of User Fee Package
News | 27 June 2012
Biotechnology Industry Organization (BIO)
Click on the link to read the full article at PharmiWeb.com (press release)
(This link will open in a new window)
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
